Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 2/20 | 0.84 |
| ▸ | SRC | P12931 | 1/20 | 0.57 |
| ▸ | CETP | P11597 | 3/20 | 0.53 |
| ▸ | PDPK1 | O15530 | 2/20 | 0.49 |
| ▸ | MTOR | P42345 | 1/20 | 0.49 |
| ▸ | AKR1C3 | P42330 | 1/20 | 0.49 |
| ▸ | ALPG | P10696 | 1/20 | 0.49 |
| ▸ | PTK2B | Q14289 | 1/20 | 0.49 |
| ▸ | FOLH1 | Q04609 | 1/20 | 0.46 |
| ▸ | BTN3A1 | O00481 | 1/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.44 |
| ▸ | NPC1 | O15118 | 1/20 | 0.43 |
| ▸ | RAB9A | P51151 | 1/20 | 0.43 |
| ▸ | NR4A1 | P22736 | 1/20 | 0.43 |
| ▸ | NR4A2 | P43354 | 1/20 | 0.43 |
| ▸ | NR4A3 | Q92570 | 1/20 | 0.43 |
| ▸ | LMNA | P02545 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1110552 | 0.92 | TSHR (0.78) | TSHRSRCCETPPDPK1MTOR | |
| SCHEMBL51316 | 0.91 | TSHR (1.00) | TSHRSRCCETPPDPK1MTOR | |
| SCHEMBL27908642 | 0.91 | TSHR (1.00) | TSHRSRCCETPPDPK1MTOR | |
| SCHEMBL6749263 | 0.90 | TSHR (0.75) | TSHRSRCCETPPDPK1MTOR | |
| Hydrochloric Acid SCHEMBL10722992 | 0.89 | TSHR (0.96) | TSHRSRCCETPPDPK1MTOR | |
| SCHEMBL9446520 | 0.89 | TSHR (0.96) | TSHRSRCCETPPDPK1MTOR | |
| SCHEMBL11756554 | 0.89 | TSHR (0.96) | TSHRSRCCETPPDPK1MTOR | |
| SCHEMBL4219700 | 0.89 | TSHR (0.96) | TSHRSRCCETPPDPK1MTOR | |
| Ammonia Solution, Strong SCHEMBL7268743 | 0.89 | TSHR (0.96) | TSHRSRCCETPPDPK1MTOR | |
| SCHEMBL28264490 | 0.89 | TSHR (0.96) | TSHRSRCCETPPDPK1MTOR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-118164856-A | Nucleoside triphosphate synthetic bulk drug and preparation method thereof | 精华制药集团南通有限公司 | 2024-06-11 | — | — | CN | disclosed |
| EP-3183257-B1 | DI- AND TRIPHOSPHATE PRODRUGS | UNIV HAMBURG (DE) | 2019-10-09 | — | — | EP | disclosed |
| WO-2019155639-A1 | PRODUCTION METHOD AND PRODUCTION INTERMEDIATE FOR GUANOSINE-3',5'-BISDIPHOSPHATE | 国立大学法人東京工業大学 | 2019-08-15 | — | — | WO | disclosed |
| WO-2019156240-A1 | PRODUCTION METHOD AND PRODUCTION INTERMEDIATE FOR GUANOSINE-3',5'-BISDIPHOSPHATE | 国立大学法人東京工業大学 | 2019-08-15 | — | — | WO | disclosed |
| US-10131685-B2 | Di- and triphosphate prodrugs | UNIVERSITAET HAMBURG (DE) | 2018-11-20 | — | — | US | disclosed |
| US-20170275328-A1 | DI- AND TRIPHOSPHATE PRODRUGS | UNIVERSITAET HAMBURG (DE) | 2017-09-28 | — | — | US | disclosed |
| EP-3183257-A1 | DI- AND TRIPHOSPHATE PRODRUGS | Universität Hamburg (DE) | 2017-06-28 | — | — | EP | disclosed |
| WO-2016026493-A1 | DI- AND TRIPHOSPHATE PRODRUGS | UNIVERSITÄT HAMBURG (DE) | 2016-02-25 | — | — | WO | disclosed |
| CN-101395158-A | Pyrrolotriazine aniline prodrug compounds useful as kinase inhibitors | BRISTOL MYERS SQUIBB CO (US) | 2009-03-25 | — | — | CN | disclosed |
| WO-1996026948-A1 | PHOSPHATE DERIVATIVES OF DISUBSTITUTED UREAS AND THIOUREAS | PHARMACIA & UPJOHN S.P.A. (IT) | 1996-09-06 | — | — | WO | disclosed |
| US-3943179-A | Hydroxylation of aromatic compounds | RHONE-POULENC TEXTILE (FR) | 1976-03-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10131685-B2 | Di- and triphosphate prodrugs | TYMP, PNP, DUT | TSHR 3782/4885SRC 3174/4885CETP 1724/4885 |
| US-20170275328-A1 | DI- AND TRIPHOSPHATE PRODRUGS | TYMP, PNP, DUT | TSHR 3782/4885SRC 3174/4885CETP 1724/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.